RXRX vs. KYMR, SDGR, RCUS, ABCL, PTCT, PCVX, EXEL, RVMD, HALO, and KRYS
Should you be buying Recursion Pharmaceuticals stock or one of its competitors? The main competitors of Recursion Pharmaceuticals include Kymera Therapeutics (KYMR), Schrödinger (SDGR), Arcus Biosciences (RCUS), AbCellera Biologics (ABCL), PTC Therapeutics (PTCT), Vaxcyte (PCVX), Exelixis (EXEL), Revolution Medicines (RVMD), Halozyme Therapeutics (HALO), and Krystal Biotech (KRYS). These companies are all part of the "medical" sector.
Kymera Therapeutics (NASDAQ:KYMR) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, community ranking, dividends and valuation.
Kymera Therapeutics has higher revenue and earnings than Recursion Pharmaceuticals. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Kymera Therapeutics received 19 more outperform votes than Recursion Pharmaceuticals when rated by MarketBeat users. However, 51.22% of users gave Recursion Pharmaceuticals an outperform vote while only 48.19% of users gave Kymera Therapeutics an outperform vote.
Kymera Therapeutics currently has a consensus price target of $42.70, suggesting a potential upside of 32.98%. Recursion Pharmaceuticals has a consensus price target of $14.33, suggesting a potential upside of 73.11%. Given Kymera Therapeutics' higher possible upside, analysts clearly believe Recursion Pharmaceuticals is more favorable than Kymera Therapeutics.
89.1% of Recursion Pharmaceuticals shares are held by institutional investors. 15.8% of Kymera Therapeutics shares are held by company insiders. Comparatively, 15.8% of Recursion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Recursion Pharmaceuticals had 4 more articles in the media than Kymera Therapeutics. MarketBeat recorded 8 mentions for Recursion Pharmaceuticals and 4 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.65 beat Recursion Pharmaceuticals' score of 0.47 indicating that Recursion Pharmaceuticals is being referred to more favorably in the news media.
Kymera Therapeutics has a net margin of -194.67% compared to Kymera Therapeutics' net margin of -765.90%. Recursion Pharmaceuticals' return on equity of -31.92% beat Kymera Therapeutics' return on equity.
Kymera Therapeutics has a beta of 2.31, suggesting that its share price is 131% more volatile than the S&P 500. Comparatively, Recursion Pharmaceuticals has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500.
Summary
Kymera Therapeutics beats Recursion Pharmaceuticals on 9 of the 17 factors compared between the two stocks.
Get Recursion Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Recursion Pharmaceuticals Competitors List
Related Companies and Tools
